For World Ovarian Cancer Day 2023, we'd like to highlight some of our most impactful research and review articles on OC in the last few years, which have extensively contributed to the field. We'd like to congratulate our authors on this achievement, which cementsJournal of Ovarian Research...
Article 02 October 2023 Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence Article Open access 29 July 2020 Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low...
For World Ovarian Cancer Day 2024, we'd like to highlight some of our most impactful research and review articles on OC in the last few years, which have extensively contributed to the field. We'd like to congratulate our authors on this achievement, which cementsJournal of Ovarian Research...
Epithelial ovarian cancer (EOC) is a deadly disease with limited diagnostic biomarkers and therapeutic targets. Here we conduct a comprehensive proteomic profiling of ovarian tissue and plasma samples from 813 patients with different histotypes and thera
Epigenetic factors have shown to be an important reason for cancer progression. Our findings at the epigenetic level includes a comparative analysis, point mutations in genes, overactivation of signaling pathways. This review paper, highlight the possible correlation between the three disorders in terms...
Epithelial ovarian cancer (OvCa) is associated with high mortality and, as the majority (>75%) of women with OvCa have metastatic disease at the time of diagnosis, rates of survival have not changed appreciably over 30 years. A mechanistic understanding of OvCa initiation and progression is hind...
Ovarian cancer (OC) is a highly aggressive gynecological malignancy prevalent worldwide. Most OC cases are typically diagnosed at advanced stages, which has led to a 5-year overall survival rate of less than 35% following conventional treatment. Furthermore, immune checkpoint inhibitor therapy has ...
OVARIAN cancerMEDICAL researchPOLY(ADP-ribose) polymeraseHYPERTHERMIC intraperitoneal chemotherapyIn the 2022 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The ...
This review elaborates the use of PARP inhibitors in ovarian cancer.Introduction As a common gynecological tumor, ovarian cancer has many different tissue types. 90% of them are epithelial cell type, and the rest are non-epithelial ovarian cancers. There are also some rare pathological types ...
Ovarian cancer (OC) is the most malignant tumor with the worst prognosis in female reproductive system. Mitophagy and long non-coding RNAs (lncRNAs) play pivotal roles in tumorigenesis, development, and drug resistance. The effects of mitophagy-related l